vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $124.7M, roughly 1.7× SMITH & WESSON BRANDS, INC.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 1.5%, a 55.8% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $16.3M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
IDYA vs SWBI — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $124.7M |
| Net Profit | $119.2M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | 52.2% | 3.3% |
| Net Margin | 57.4% | 1.5% |
| Revenue YoY | — | -3.9% |
| Net Profit YoY | 330.1% | -53.6% |
| EPS (diluted) | $1.33 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.7M | ||
| Q3 25 | $207.8M | $85.1M | ||
| Q2 25 | — | $140.8M | ||
| Q1 25 | — | $115.9M | ||
| Q4 24 | — | $129.7M | ||
| Q3 24 | $0 | $88.3M | ||
| Q2 24 | $0 | $159.1M | ||
| Q1 24 | $0 | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | $119.2M | $-3.4M | ||
| Q2 25 | — | $8.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-51.8M | $-1.9M | ||
| Q2 24 | $-52.8M | $27.9M | ||
| Q1 24 | $-39.6M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 52.2% | -3.5% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 57.4% | -4.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | -2.1% | ||
| Q2 24 | — | 17.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $1.33 | $-0.08 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-0.60 | $-0.04 | ||
| Q2 24 | $-0.68 | $0.60 | ||
| Q1 24 | $-0.53 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $363.2M |
| Total Assets | $1.2B | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.4M | ||
| Q3 25 | $786.9M | $18.0M | ||
| Q2 25 | — | $25.2M | ||
| Q1 25 | — | $26.7M | ||
| Q4 24 | — | $39.1M | ||
| Q3 24 | $920.0M | $35.5M | ||
| Q2 24 | $701.7M | $60.8M | ||
| Q1 24 | $698.8M | $47.4M |
| Q4 25 | — | $363.2M | ||
| Q3 25 | $1.1B | $364.4M | ||
| Q2 25 | — | $372.5M | ||
| Q1 25 | — | $366.9M | ||
| Q4 24 | — | $371.5M | ||
| Q3 24 | $1.2B | $380.0M | ||
| Q2 24 | $931.7M | $399.9M | ||
| Q1 24 | $935.3M | $376.4M |
| Q4 25 | — | $548.6M | ||
| Q3 25 | $1.2B | $554.6M | ||
| Q2 25 | — | $559.6M | ||
| Q1 25 | — | $578.9M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | $1.2B | $571.3M | ||
| Q2 24 | $973.7M | $577.4M | ||
| Q1 24 | $961.5M | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $27.3M |
| Free Cash FlowOCF − Capex | $142.2M | $16.3M |
| FCF MarginFCF / Revenue | 68.4% | 13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | 1.19× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | $142.2M | $-8.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $-9.8M | ||
| Q4 24 | — | $-7.4M | ||
| Q3 24 | $-49.2M | $-30.8M | ||
| Q2 24 | $-32.9M | $43.7M | ||
| Q1 24 | $-43.8M | $25.2M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $142.2M | $-12.4M | ||
| Q2 25 | — | $33.5M | ||
| Q1 25 | — | $-16.1M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | $-49.7M | $-35.5M | ||
| Q2 24 | $-33.9M | $38.2M | ||
| Q1 24 | $-45.1M | $7.0M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | 68.4% | -14.6% | ||
| Q2 25 | — | 23.8% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | — | -8.3% | ||
| Q3 24 | — | -40.2% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
